First National Bank & Trust Co. of Newtown Sells 35 Shares of Amgen Inc. (NASDAQ:AMGN)

First National Bank & Trust Co. of Newtown lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,770 shares of the medical research company’s stock after selling 35 shares during the quarter. First National Bank & Trust Co. of Newtown’s holdings in Amgen were worth $553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of AMGN. Horizon Financial Services LLC purchased a new position in Amgen in the first quarter valued at about $28,000. United Community Bank bought a new position in Amgen in the 4th quarter worth approximately $29,000. Delos Wealth Advisors LLC grew its stake in Amgen by 2,500.0% in the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares in the last quarter. Bbjs Financial Advisors LLC purchased a new stake in shares of Amgen during the second quarter worth $33,000. Finally, Western Pacific Wealth Management LP bought a new position in shares of Amgen in the fourth quarter worth $37,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 1.4 %

NASDAQ:AMGN traded down $4.62 during mid-day trading on Thursday, hitting $324.53. 2,171,957 shares of the company’s stock traded hands, compared to its average volume of 2,587,917. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The company has a market capitalization of $174.09 billion, a P/E ratio of 46.24, a P/E/G ratio of 2.78 and a beta of 0.58. The company has a fifty day moving average of $321.57 and a 200 day moving average of $299.40. Amgen Inc. has a twelve month low of $248.38 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). The company had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business’s revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the company earned $5.00 EPS. On average, analysts forecast that Amgen Inc. will post 19.5 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.77%. The ex-dividend date was Friday, August 16th. Amgen’s payout ratio is 128.57%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Argus upped their price target on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price target (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $230.00 to $300.00 in a research note on Friday, May 3rd. Finally, Mizuho boosted their price objective on Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Eleven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $326.89.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.